SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on a preclinical product candidate, XP23829, at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii. The poster, which is entitled “Comparison of the Efficacy and Tolerability of a Novel Methyl Hydrogenfumarate (MHF) Prodrug with Dimethylfumarate (DMF) in Rodent EAE and GI Irritation Models,” will be presented at Poster Session V, Wednesday, April 13, from 2:00 p.m. to 6:30 p.m. Hawaii-Aleutian Standard Time.
